unknown
Stage
About
Calyxha is a private biotechnology company developing novel small-molecule anti-inflammatory drugs targeting multiple inflammatory diseases. Its lead candidate, CAL-4, is being developed as a potential corticosteroid alternative for asthma and is in preclinical development with planned clinical entry by 2024.
Explore Calyxha's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.